Dual Targeting of the Androgen Receptor for Effective and Durable Control of Lethal Prostate Cancer [ 2017 - 2020 ]

Research Grant

Researchers: Prof Wayne Tilley (Principal investigator) ,  Dr Luke Selth ,  Dr Renea Taylor ,  Prof Gail Risbridger

Brief description Preventing binding of androgens to the androgen receptor is the mainstay treatment for advanced prostate cancer, but resistance inevitably develops and the disease becomes lethal. We will develop a new drug that targets a part of the androgen receptor unrelated to its androgen binding function to overcome resistance to current therapy. As this drug will be effective in all stages of prostate cancer, it has high potential to improve survival outcomes for men with prostate cancer.

Funding Amount $AUD 969,621.45

Funding Scheme Project Grants

Notes Standard Project Grant